Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science

Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair. The post Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science appeared…

Read More

Fractyl’s Weight Maintenance Device Meets Clinical Goal, but Shares Nosedive, Layoffs Follow

Fractyl Health reported positive six-month trial results from an investigation of its Revita procedure last week, but shares of Fractyl stock dropped steeply on October 16 immediately following the announcement. Despite the positive findings, the stock’s sharp decline highlighted a contrast between the clinical findings and the market’s response. The post Fractyl’s Weight Maintenance Device…

Read More

How Crothall Healthcare’s Support Services Strengthen Healthcare Operations

Behind every safe, efficient healthcare facility is a network of essential support services. Our specialized teams, proven processes, and innovative technologies help healthcare organizations improve operations, support clinicians, and create safer, more positive patient experiences. Environmental Services Enhance patient safety, experience, and trust through evidence-based infection prevention programs, leading-edge technology, and service excellence that create…

Read More

Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition

Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a majority stake in Aurion Biotech, a startup developing a corneal cell therapy. The post Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition appeared first on MedCity…

Read More